Hoth Therapeutics Inc
NASDAQ:HOTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
US |
|
PAMT Corp
NASDAQ:PAMT
|
US |
|
Bowlin Travel Centers Inc
OTC:BWTL
|
US |
|
M
|
Mingyue Optical Lens Co Ltd
SZSE:301101
|
CN |
|
R
|
Right Way Industrial Co Ltd
TWSE:1506
|
TW |
|
Qianhe Condiment and Food Co Ltd
SSE:603027
|
CN |
|
K
|
Krebs Biochemicals and Industries Ltd
NSE:KREBSBIO
|
IN |
|
S
|
Shenzhen Dynanonic Co Ltd
SZSE:300769
|
CN |
|
Pro Medicus Ltd
ASX:PME
|
AU |
|
Byron Energy Ltd
ASX:BYE
|
AU |
|
P
|
Powszechny Zaklad Ubezpieczen SA
WSE:PZU
|
PL |
Hoth Therapeutics Inc
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.
